Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Moderna (NASDAQ:MRNA) is planning to launch a messenger-RNA-based vaccine for skin cancer as early as next year, Japanese ...

In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

The US Department of Agriculture (USDA) has taken a significant step towards the approval of an H5N1 avian flu vaccine for ...

V503-064 is a Phase 3, double-blind, placebo-controlled clinical study ( NCT04635423 ) to evaluate the safety/tolerability and efficacy of GARDASIL 9 (V503) in preventing HPV-related anogenital ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Vaxcyte Inc.’s stock soared 42% Tuesday, after the vaccine maker reported positive results from an early-stage trial of its ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

A recent decision by USDA could pave the way for an H5N1 avian flu vaccine for dairy cows by as early as the first quarter of ...

NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market ...